Intelligent Bio Solutions Inc. · NASDAQ:INBS
Intelligent Bio Solutions — Investor Presentation (October 2026)
25 slides from Intelligent Bio Solutions's investor presentation, Oct 13, 2026
Slide 1: Pioneering Pain-free Solutions
INTELLIGENT BIO SOLUTIONS Pioneering Pain-free Solutions Transforming drug testing with non-invasive, cost-effective, reliable solutions. NASDAQ: INBS | October 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities L
Slide 3: We are a medical technology company
We are a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our mission is to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Slide 4: Simpler Drug Testing
Slide 5: Steps to Simpler Drug Testing
3 Steps to Simpler Drug Testing 1 Donor places the tip of each finger on the fingerprint collection area for 5seconds. 2 Test administrator inserts the cartridge into the digital reader. 3 The reader provides results in less than 10 minutes*. *INBS has commenced a Validation Study for a rapid drug s
Slide 6: NASDAQ: INBS 6
NASDAQ: INBS 6
Slide 7: Installed Readers in the Market
NASDAQ: INBS. Installed Readers in the Market € 2000 1500 1000 Drug Screening Reader fo) a (Ix sale) FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 ; Cartridge Sales YS ‘ 500,000 We WN " 400,000 | rs 300,000 Al = 200,000 Disposable Drug 100,000 | | | Screening Cartridge fo) I (recurring revenue) FY
Slide 8: Full Year Revenue & Gross Margin
Full Year Revenue & Gross Margin Revenue ($M) for the Period Ending 30 June Gross Margin for the Period Ending 30 June $45 $4.21 65% | x | ae $09 50% 48.6% 45% 40.8% . 7 35% FY 2026, FY 2025 FY 2026 $3.05 . a $25 $0.7 $15, $10 $05 $- FY 2025 Cartridges Readers mAccessories
Slide 9: Customer Accounts
Customer Accounts 500+ Active Accounts Sold into 35 Countries & Territories NASDAQ: INBS PlHegarty Ey Total Recycling ae Hill FastenZ PREMIER 7 RobinsonBrothers Over explore @ MeCse@ MPRINCENULD ie @ abellio” earth s i ra o PRESSGLASS Smurfit alletways Ss boughey CROWN Beas LCD Rats Hertpoceie Sones
Slide 10: Anticipated Milestones & Timing
Anticipated Milestones & Timing Milestone Clinical data collection across the Company's FDA 510(k) clinical study program Analysis, compilation and finalization of 510(k) submission package Submission of package seeking FDA 510(k) clearance for the opiate codeine If FDA 510(k) clearance received in
Slide 11: Intelligent Fingerprinting Drug Testing
= SoSe SSeS OO ing t ingerprin Intelligent F Drug Testing
Slide 12: Consumption
Consumption The journey of a drug through the body: Absorption: how the drug moves from the site of administration to the site of action. Distribution: the journey of the drug through the bloodstream to various tissues of the body. Metabolism: the process that breaks down the drug. Excretion: the re
Slide 13: Benefits of Fingerprint Drug Testing
Benefits of ww Fingerprint ANS th Y Drug Testing Reduce Risk Save Costs Increase Efficiency Aim to identify current testing Rapidly collect samples ratherthan past —_ in-house and eliminate and employ batch testing use with a detection the need for specialized to analyze drug screening of up to 16-2
Slide 14: Intelligent Fingerprinting vs Urine & Saliva Drug Testing
Intelligent Fingerprinting vs Urine & Saliva Drug Testing Fingerprint Detection Window Up to 16 - 24 hours Up to 2 days Up to 4 days Less than 10 minutes Average Test Time (2-3 mins when batch testing) Up to 20 minutes 20 minutes — 4 hours or more Average Annual Cost * ~ $5,500 ~ $7,600 ~ $7,750 Acc
Slide 15: Opportunity
e Opportunity Leveraging intelligent, non-invasive testing to address global demands. Market
Slide 16: FDA 510(k) clinical work completed
and 100% d Work Clinical cut-off study for codeine v Multi-site method comparison v Usability study Vv Interference study Vv Precision testing - over 1,600 tests v Cybersecurity / penetration testing Vv Software / SBOM issues Resolved New 510(k) submission Vv Sep 2026
Slide 17: Addressing a $400 Billion Substance Abuse Problem
Addressing a $400 Billion Substance Abuse Problem! The Drug Screening Market is projected to reach US$13.1 billion in 2026 and is expected to reach US$31 billion by 2032, growing at a CAGR of 15.4%. Market Drivers Workplace safety compliance in high-risk industries Rising substance use concerns Focu
Slide 18: NASDAQ: INBS 18
NASDAQ: INBS 18
Slide 19: Athlete testing, flight crews, point-of-care and offshore use cases
Athlete testing (Professional, Collegiate and Schools) Flight and ground crews Pre-boarding screening Random at sea or incident testing (no labs available) Point-of-care drug screening Emergency rooms (time is critical) Offshore oil & gas (remote locations)
Slide 20: Growing Drug Consumption
Growing Drug Consumption Approximately 331 million people used an illicit drug in 2024, a 34% increase over the last 10 years. 256 63 32 25 million million million million cannabis users, opioid users, amphetamine users, cocaine users, representing representing 4.8% of the representing 1.2% of the r
Slide 21: More Than 70% of Adults Abusing Alcohol or Illicit Drugs Are Employed
More Than 70% of Adults Abusing Alcohol or Illicit Drugs in the U.S. Are Employed! Illicit drugs are a continuing issue, contributing to accidents in the workplace. In 2024, the combined U.S. workforce urine drug positivity rate was 4.4%, with a 4% or higher overall drug positivity rate persisting o
Slide 22: Percentage of Establishments Testing New and Current Employees
Percentage of Establishments Testing New and Current Employees! Transportation and warehousing Retail trade Wholesale trade : Manufacturing Construction Utilities Natural resources and mining Total U.S., private sector 0% 10% 20% 30% 40% 50% 60% AQ: INBS in ™ Charts new applicants or current employe
Slide 23: Common Stock Issued
NASDAQ: INBS. Common Stock Issued Pre-funded Warrants Total Common Equivalent Shares’ Warrants (WAEP - $4.66) “No ratchets or resets. 3,316,803 2,646,084 5,962,887 9,399,018 N Ww
Slide 24: Summary
Summary NASDAQ: INBS Large growing customer base with 1,886 installed readers and 502 active customers as of June 30, 2026. Increased revenue and growth, utilizing the Razor/Razor-blade model. FDA 510(k) package submitted in September 2026, seeking U.S. market clearance. Method Comparison Study deli
Slide 25: Thank You
Thank You www.ibs.inc | info@ibs.inc NASDAQ: INBS.
Intelligent Bio Solutions — Investor Presentation (October 2026) on 6ix